Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price gapped down prior to trading on Monday . The stock had previously closed at $25.05, but opened at $23.28. Ascentage Pharma Group International shares last traded at $23.28, with a volume of 167 shares trading hands.

Analysts Set New Price Targets

A number of analysts recently issued reports on AAPG shares. Piper Sandler assumed coverage on Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price objective for the company. Oppenheimer initiated coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price objective on the stock. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price on the stock. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Finally, Truist Financial set a $51.00 target price on shares of Ascentage Pharma Group International in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $48.40.

Ascentage Pharma Group International Stock Down 4.6%

The firm’s 50-day moving average is $25.74 and its 200 day moving average is $32.56. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. UBS Group AG increased its position in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares in the last quarter. XY Capital Ltd raised its position in Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the period. Tema Etfs LLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter worth about $610,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International during the 3rd quarter valued at about $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.